CD244<sup>+</sup> polymorphonuclear myeloid‑derived suppressor cells reflect the status of peritoneal dissemination in a colon cancer mouse model

Sugita,Yutaka; Yamashita,Kimihiro; Fujita,Mitsugu; Saito,Masafumi; Yamada,Kota; Agawa,Kyosuke; Watanabe,Akihiro; Fukuoka,Eiji; Hasegawa,Hiroshi; Kanaji,Shingo; Oshikiri,Taro; Matsuda,Takeru; Nakamura,Tetsu; Suzuki,Satoshi; Kakeji,Yoshihiro

doi:10.3892/or.2021.8057

CD244⁺ polymorphonuclear myeloid‑derived suppressor cells reflect the status of peritoneal dissemination in a colon cancer mouse model

Authors:
- Yutaka Sugita
- Kimihiro Yamashita
- Mitsugu Fujita
- Masafumi Saito
- Kota Yamada
- Kyosuke Agawa
- Akihiro Watanabe
- Eiji Fukuoka
- Hiroshi Hasegawa
- Shingo Kanaji
- Taro Oshikiri
- Takeru Matsuda
- Tetsu Nakamura
- Satoshi Suzuki
- Yoshihiro Kakeji
View Affiliations

Affiliations: Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo 650‑0017, Japan, Department of Disaster and Emergency and Critical Care Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo 650‑0017, Japan, Department of Gastroenterological Surgery, Hyogo Cancer Center, Akashi, Hyogo 673‑8558, Japan, Division of Community Medicine and Medical Network, Department of Social Community Medicine and Health Science, Kobe University Graduate School of Medicine, Kobe, Hyogo 650‑0017, Japan
Published online on: April 19, 2021 https://doi.org/10.3892/or.2021.8057
Article Number: 106
Copyright: © Sugita et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the recent development of chemotherapeutic agents, the prognosis of colorectal cancer (CRC) patients with peritoneal dissemination (PD) remains poor. The tumor immune microenvironment (TIME) has drawn attention as a key contributing factor of tumor progression. Of TIME components, myeloid‑derived suppressor cells (MDSCs) are considered to play a responsible role in the immunosuppressive characteristics of the TIME. MDSCs are classified into two major subsets: Monocytic MDSCs (M‑MDSCs) and polymorphonuclear MDSCs (PMN‑MDSCs). Therefore, we hypothesize that MDSCs would play important roles in the PD‑relevant TIME and PD progression. To address this hypothesis, we established PD mouse models. As the PD nodules consisted scarcely of immune cells, we focused on the peritoneal cavity, but not PD nodule, to evaluate the PD‑relevant TIME. As a result, intraperitoneal PMN‑MDSCs were found to be substantially increased in association with PD progression. Based on these results, we phenotypically and functionally verified the usefulness of CD244 for identifying PMN‑MDSCs. In addition, the concentrations of interleukin (IL)‑6 and granulocyte‑colony stimulating factor (G‑CSF) were significantly increased in the peritoneal cavity, both of which were produced by the tumors and thought to contribute to the increases in the PMN‑MDSCs. In vivo depletion of the PMN‑MDSCs by anti‑Ly6G monoclonal antibody (mAb) significantly inhibited the PD progression and reverted CD4⁺ and CD8⁺ T cells in the peritoneal cavity and the peripheral blood. Collectively, these results suggest that the targeted therapy for PMN‑MDSCs would provide not only new therapeutic value but also a novel strategy to synergize with T‑cell‑based immunotherapy for CRC‑derived PD.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Massalou D, Benizri E, Chevallier A, Duranton-Tanneur V, Pedeutour F, Benchimol D and Béréder JM: Peritoneal carcinomatosis of colorectal cancer: Novel clinical and molecular outcomes. Am J Surg. 213:377–387. 2017. View Article : Google Scholar : PubMed/NCBI
3	Sugarbaker PH: Colorectal cancer: Prevention and management of metastatic disease. BioMed Res Int. 2014:7828902014. View Article : Google Scholar : PubMed/NCBI
4	Segelman J, Granath F, Holm T, Machado M, Mahteme H and Martling A: Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 99:699–705. 2012. View Article : Google Scholar : PubMed/NCBI
5	Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, de Hingh IH and Punt CJ: Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 38:617–623. 2012. View Article : Google Scholar : PubMed/NCBI
6	Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, et al: Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 17:1709–1719. 2016. View Article : Google Scholar : PubMed/NCBI
7	Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
8	Fridman WH, Zitvogel L, Sautès-Fridman C and Kroemer G: The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 14:717–734. 2017. View Article : Google Scholar : PubMed/NCBI
9	Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, Yang SR, Kurian A, Van Valen D, West R, et al: A Structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 174:1373–1387.e19. 2018. View Article : Google Scholar : PubMed/NCBI
10	Peltanova B, Raudenska M and Masarik M: Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: A systematic review. Mol Cancer. 18:632019. View Article : Google Scholar : PubMed/NCBI
11	Veglia F, Perego M and Gabrilovich D: Myeloid-derived suppressor cells coming of age. Nat Immunol. 19:108–119. 2018. View Article : Google Scholar : PubMed/NCBI
12	Gabrilovich DI, Ostrand-Rosenberg S and Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 12:253–268. 2012. View Article : Google Scholar : PubMed/NCBI
13	Otsubo D, Yamashita K, Fujita M, Nishi M, Kimura Y, Hasegawa H, Suzuki S and Kakeji Y: Early-phase treatment by Low-dose 5-Fluorouracil or primary tumor resection inhibits MDSC-mediated lung metastasis formation. Anticancer Res. 35:4425–4431. 2015.PubMed/NCBI
14	Tanaka T, Fujita M, Hasegawa H, Arimoto A, Nishi M, Fukuoka E, Sugita Y, Matsuda T, Sumi Y, Suzuki S, et al: Frequency of Myeloid-derived suppressor cells in the peripheral blood reflects the status of tumor recurrence. Anticancer Res. 37:3863–3869. 2017.PubMed/NCBI
15	Youn JI, Nagaraj S, Collazo M and Gabrilovich DI: Subsets of Myeloid-Derived suppressor cells in tumor bearing mice. J Immunol. 181:5791–5802. 2008. View Article : Google Scholar : PubMed/NCBI
16	Fortin C, Huang X and Yang Y: NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells. J Immunol. 189:1843–1849. 2012. View Article : Google Scholar : PubMed/NCBI
17	Cassetta L, Baekkevold ES, Brandau S, Bujko A, Cassatella MA, Dorhoi A, Krieg C, Lin A, Loré K, Marini O, et al: Deciphering myeloid-derived suppressor cells: Isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother. 68:687–697. 2019. View Article : Google Scholar : PubMed/NCBI
18	Agresta L, Hoebe KHN and Janssen EM: The emerging role of CD244 signaling in immune cells of the tumor microenvironment. Front Immunol. 9:28092018. View Article : Google Scholar : PubMed/NCBI
19	Wu Y, Kuang DM, Pan WD, Wan YL, Lao XM, Wang D, Li XF and Zheng L: Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology. 57:1107–1116. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wherry EJ and Kurachi M: Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI
21	Youn JI, Collazo M, Shalova IN, Biswas SK and Gabrilovich DI: Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 91:167–181. 2012. View Article : Google Scholar : PubMed/NCBI
22	Clarke P, Mann J, Simpson JF, Rickard-Dickson K and Primus FJ: Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 58:1469–1477. 1998.PubMed/NCBI
23	Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, Naka T, Ishida K, Primus FJ and Yamaue H: Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int J Cancer. 120:585–593. 2007. View Article : Google Scholar : PubMed/NCBI
24	Kilkenny C, Browne WJ, Cuthill IC, Emerson M and Altman DG: Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol. 8:e10004122010. View Article : Google Scholar : PubMed/NCBI
25	Feldman AT and Wolfe D: Tissue processing and hematoxylin and eosin staining. Methods Mol Biol. 1180:31–43. 2014. View Article : Google Scholar : PubMed/NCBI
26	Arimoto A, Yamashita K, Hasegawa H, Sugita Y, Fukuoka E, Tanaka T, Suzuki S and Kakeji Y: Immunosuppression induced by perioperative peritonitis promotes lung metastasis. Anticancer Res. 38:4333–4338. 2018. View Article : Google Scholar : PubMed/NCBI
27	Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA and Brandau S: How to measure the immunosuppressive activity of MDSC: Assays, problems and potential solutions. Cancer Immunol Immunother. 68:631–644. 2019. View Article : Google Scholar : PubMed/NCBI
28	Shang W, Tang Z, Gao Y, Qi H, Su X, Zhang Y and Yang R: LncRNA RNCR3 promotes Chop expression by sponging miR-185-5p during MDSC differentiation. Oncotarget. 8:111754–111769. 2017. View Article : Google Scholar : PubMed/NCBI
29	Schleicher U, Paduch K, Debus A, Obermeyer S, König T, Kling JC, Ribechini E, Dudziak D, Mougiakakos D, Murray PJ, et al: TNF-mediated restriction of arginase 1 expression in myeloid cells triggers type 2 NO synthase activity at the site of infection. Cell Rep. 15:1062–1075. 2016. View Article : Google Scholar : PubMed/NCBI
30	Agresta L, Lehn M, Lampe K, Cantrell R, Hennies C, Szabo S, Wise-Draper T, Conforti L, Hoebe K and Janssen EM: CD244 represents a new therapeutic target in head and neck squamous cell carcinoma. J Immunother Cancer. 8:e0002452020. View Article : Google Scholar : PubMed/NCBI
31	Morris KT, Khan H, Ahmad A, Weston LL, Nofchissey RA, Pinchuk IV and Beswick EJ: G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration. Br J Cancer. 110:1211–1220. 2014. View Article : Google Scholar : PubMed/NCBI
32	Kawano M, Mabuchi S, Matsumoto Y, Sasano T, Takahashi R, Kuroda H, Kozasa K, Hashimoto K, Isobe A, Sawada K, et al: The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. Sci Rep. 5:182172015. View Article : Google Scholar : PubMed/NCBI
33	Pilatova K, Bencsikova B, Demlova R, Valik D and Zdrazilova-Dubska L: Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: Considerations for granulocyte colony-stimulating factor treatment. Cancer Immunol Immunother. 67:1919–1929. 2018. View Article : Google Scholar : PubMed/NCBI
34	Veglia F, Sanseviero E and Gabrilovich DI: Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. Feb 1–2021.(Epub ahead of print). doi: 10.1038/s41577-020-00490-y. View Article : Google Scholar : PubMed/NCBI
35	Ceelen W, Ramsay RG, Narasimhan V, Heriot AG and De Wever O: Targeting the tumor microenvironment in colorectal peritoneal metastases. Trends Cancer. 6:236–246. 2020. View Article : Google Scholar : PubMed/NCBI
36	Toyoshima M, Tanaka Y, Matumoto M, Yamazaki M, Nagase S, Sugamura K and Yaegashi N: Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging. Luminescence. 24:324–331. 2009. View Article : Google Scholar : PubMed/NCBI
37	Taibi A, Albouys J, Jacques J, Perrin ML, Yardin C, Durand Fontanier S and Bardet SM: Comparison of implantation sites for the development of peritoneal metastasis in a colorectal cancer mouse model using non-invasive bioluminescence imaging. PLoS One. 14:e02203602019. View Article : Google Scholar : PubMed/NCBI
38	Lee YS, Lee WS, Kim CW, Lee SJ, Yang H, Kong SJ, Ning J, Yang KM, Kang B, Kim WR, et al: Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer. J Immunother Cancer. 8:e0008572020. View Article : Google Scholar : PubMed/NCBI
39	Cassim S and Pouyssegur J: Tumor microenvironment: A metabolic player that shapes the immune response. Int J Mol Sci. 21:1572019. View Article : Google Scholar : PubMed/NCBI
40	Condamine T and Gabrilovich DI: Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32:19–25. 2011. View Article : Google Scholar : PubMed/NCBI
41	Waight JD, Hu Q, Miller A, Liu S and Abrams SI: Tumor-Derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One. 6:e276902011. View Article : Google Scholar : PubMed/NCBI
42	Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, Utikal J and Umansky V: IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol. 359:1042542021. View Article : Google Scholar : PubMed/NCBI
43	Kramer ED and Abrams SI: Granulocytic myeloid-derived suppressor cells as negative regulators of anticancer immunity. Front Immunol. 11:19632020. View Article : Google Scholar : PubMed/NCBI
44	Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, et al: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 42:2433–2453. 2006. View Article : Google Scholar : PubMed/NCBI
45	Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, et al: NCCN guidelines insights: Hematopoietic growth factors, version 1.2020. J Natl Compr Canc Netw. 18:12–22. 2020. View Article : Google Scholar : PubMed/NCBI
46	Lyman GH, Yau L, Nakov R and Krendyukov A: Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol. 29:1903–1910. 2018. View Article : Google Scholar : PubMed/NCBI
47	Fan Z, Li Y, Zhao Q, Fan L, Tan B, Zuo J, Hua K and Ji Q: Highly expressed granulocyte colony-stimulating factor (G-CSF) and granulocyte colony-stimulating factor receptor (G-CSFR) in human gastric cancer leads to poor survival. Med Sci Monit. 24:1701–1711. 2018. View Article : Google Scholar : PubMed/NCBI
48	Moses K, Klein JC, Männ L, Klingberg A, Gunzer M and Brandau S: Survival of residual neutrophils and accelerated myelopoiesis limit the efficacy of antibody-mediated depletion of Ly-6G⁺ cells in tumor-bearing mice. J Leukoc Biol. 99:811–823. 2016. View Article : Google Scholar : PubMed/NCBI
49	Law AM, Valdes-Mora F and Gallego-Ortega D: Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 9:5612020. View Article : Google Scholar : PubMed/NCBI
50	Vetsika EK, Koukos A and Kotsakis A: Myeloid-Derived suppressor cells: Major figures that shape the immunosuppressive and angiogenic network in cancer. Cells. 8:16472019. View Article : Google Scholar : PubMed/NCBI
51	Coffelt SB, Wellenstein MD and de Visser KE: Neutrophils in cancer: Neutral no more. Nature Reviews Cancer. 16:431–446. 2016. View Article : Google Scholar : PubMed/NCBI
52	Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, et al: CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell. 29:832–845. 2016. View Article : Google Scholar : PubMed/NCBI
53	Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, et al: Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 4:e1268532019. View Article : Google Scholar : PubMed/NCBI
54	Kurachi M: CD8⁺ T cell exhaustion. Semin Immunopathol. 41:327–337. 2019. View Article : Google Scholar : PubMed/NCBI
55	Martinez M and Moon EK: CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 10:1282019. View Article : Google Scholar : PubMed/NCBI